No More TV Drug Ads? Don’t Hold Your Breath

To close out the year, The Big Story team is posting one of our favorite AdExchanger Talks episodes of 2024. Who better to give her take on programamtic transparency than an ex-FBI agent? Listen to this interview with Sherine Ebadi, Kroll managing director of investigations, who worked on the ANA's transparency report.

The IAB gave us new retail media standards for Christmas. But will the industry actually adopt them? Also, we discuss where the use of AI in advertising could be headed in 2025.

Omnicom is acquiring IPG. We unpack the nuances of the proposed deal with ad agency expert Brian Wieser, founder of the constancy Madison and Wall.

This year, Black Friday stretched on for more than a week. And the retail holiday is evolving as online shopping takes over.  

It's Thanksgiving, so we are sharing our podcast feed by posting an episode of AdExchanger Talks. Recorded right after the closing arguments of US vs. Google, ad tech antitrust edition, Digital Content Next CEO Jason Kint shares insights from inside the courtroom.

The odds of RFK Jr. implementing a ban on TV drug ads are slim, says our guest this week, BranchLab’s Josh Walsh. Still, pharma advertisers could face other regulatory changes over the next four years. Plus: We break down Forrester’s picks for the top 10 SSPs.

Jessica Alter, co-founder of the nonprofit Tech for Campaigns, believes political campaigns should model their digital ad strategy on that of seed-stage startups. She joins the podcast this week to talk through this year’s unexpected election results.

Trump won the 2024 election. To discuss how paid media played a role (and didn't) in his victory, we bring on guest Jordan Lieberman, CEO of Power Interactive. The programmatic buying company handled more than 1,000 digital campaigns across the political spectrum this election cycle.

To explain Forrester’s latest creative ad tech wave, we bring on author, Senior Analyst Nikhil Lai. Then, the untold story of how Prebid.org became an independent industry organization.

We discuss the rise of curation in programmatic buying and the current backlash. Is curation an ad network with new window dressing? And will it save or undermine the open web?